Fidelity SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences > Biotech Values

The estimated patent date of Remicade and Rituxan

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
rwdm Member Profile
 
Followed By 2
Posts 73
Boards Moderated 0
Alias Born 07/19/10
160x600 placeholder
Dow Rings Up Eighth Triple-digit Gain In October
The Dow Jones Industrial Average vaulted higher on Thursday trading, dragging the other major U.S. benchmarks higher as well.
Top Equities Stories Of The Day
European Markets Show Signs of Stress--2nd Update
ADR Shares End Mixed; Sanofi, Banco Bilbao Vizcaya Argentaria Shares Fall
Shire Files 8K - Other Events
Apple CEO Says He's 'Proud to Be Gay'
Stoxx 600 Flirts With Three-week High
U.S. Stocks, Bonds Dip on Fed Outlook
FTSE 100 Ends Higher After Roller-coaster Day
European Stocks Climb For Third Straight Day
rwdm   Thursday, 07/29/10 02:07:10 PM
Re: None
Post # of 183388 
The estimated patent date of Remicade and Rituxan in Europe are 2014 and 2015 respectively. In the US both expiry dates are in 2018. Is this because of Genentech's Cabily patent? If yes, does this mean that the expiry date of most of the mabs in US is 2018?

Is Teva's Rituximab TL011, which is starting nowadays clinical trials, in the regulatory pathway of BLA or as a biosimilar?

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist